HIMS,AMRX Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Feb 10, 3:50 PMBank of America cuts its Hims & Hers price target to $13 while reiterating an Underperform rating, citing heightened legal and regulatory risks to the company’s GLP-1 compounding business.

Peers: ELF LFMD PRGO TDOC GDRX AMWL DOCS CLOV RXRX TWST

| Held by: VTI VB IJH IWM VBK VXF VTWO XMMO IWO MDY

Index	RUT	P/E	30.86	EPS (ttm)	0.54	Insider Own	9.14%	Shs Outstand	219.12M	Perf Week	-31.60%
Market Cap	3.80B	Forward P/E	28.68	EPS next Y	0.58	Insider Trans	-6.93%	Shs Float	206.84M	Perf Month	-48.39%
Enterprise Value	4.29B	PEG	2.48	EPS next Q	0.04	Inst Own	91.52%	Short Float	37.11%	Perf Quarter	-59.34%
Income	133.79M	P/S	1.72	EPS this Y	-12.39%	Inst Trans	13.44%	Short Ratio	3.70	Perf Half Y	-65.20%
Sales	2.21B	P/B	6.54	EPS next Y	25.32%	ROA	9.44%	Short Interest	76.76M	Perf YTD	-48.60%
Book/sh	2.55	P/C	6.03	EPS next 5Y	11.56%	ROE	26.21%	52W High	72.98 -77.13%	Perf Year	-61.70%
Cash/sh	2.77	P/FCF	32.73	EPS past 3/5Y	- 17.22%	ROIC	7.89%	52W Low	16.35 2.08%	Perf 3Y	73.67%
Dividend Est.	-	EV/EBITDA	24.60	Sales past 3/5Y	75.77% -	Gross Margin	65.40%	Volatility	14.22% 8.30%	Perf 5Y	-21.94%
Dividend TTM	-	EV/Sales	1.94	EPS Y/Y TTM	28.15%	Oper. Margin	5.96%	ATR (14)	2.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.64	Sales Y/Y TTM	78.02%	Profit Margin	6.05%	RSI (14)	15.56	Recom	2.63
Dividend Gr. 3/5Y	- -	Current Ratio	1.88	EPS Q/Q	-80.29%	SMA20	-37.63%	Beta	2.50	Target Price	33.31
Payout	0.00%	Debt/Eq	1.92	Sales Q/Q	49.16%	SMA50	-47.94%	Rel Volume	1.61	Prev Close	17.24
Employees	1637	LT Debt/Eq	1.92	Earnings	Feb 23 AMC	SMA200	-63.43%	Avg Volume	20.77M	Price	16.69
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-36.37% 3.23%	Trades		Volume	33,350,097	Change	-3.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-26	Initiated	Evercore ISI	In-line	$33
Dec-09-25	Initiated	Barclays	Overweight	$48
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy	$61 → $65
Apr-29-25	Downgrade	TD Cowen	Buy → Hold	$30
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$42 → $60
Jan-10-25	Downgrade	Citigroup	Neutral → Sell	$24 → $25
Jan-07-25	Initiated	BTIG Research	Buy	$35
Dec-17-24	Initiated	Morgan Stanley	Overweight	$42
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy	$24
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral	$16 → $20
Apr-16-24	Downgrade	Jefferies	Buy → Hold	$17 → $15
Apr-10-24	Initiated	Canaccord Genuity	Buy	$20
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform	$16
Feb-26-24	Initiated	Leerink Partners	Market Perform	$10
Dec-07-23	Initiated	Imperial Capital	In-line	$9
Jul-28-23	Initiated	TD Cowen	Outperform	$11

Show Previous Ratings

Today 11:56AM	Telehealth stocks pressured as Amazon Pharmacy expands prescription delivery (Investing.com)
11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
08:59AM	Taking the new Wegovy pill every day is really complicated. Will patients stick with it? (MarketWatch)
06:46AM	Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning (Benzinga)
Feb-10-26 07:21PM	Analyst Report: Hims & Hers Health, Inc. (Morningstar Research) -10.81%
03:48PM	Loading…
03:48PM	Taking the new Wegovy pill every day is really complicated. Will patients stick with it? (MarketWatch)
10:23AM	Novo Nordisk opens new front with patent suit over Hims Wegovy copies (Reuters Videos)
09:59AM	As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? (Barchart)
08:51AM	Hims & Hers says Novo Nordisk lawsuit blatant attack on millions of Americans (TipRanks)
07:11AM	Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide (Zacks)
03:02AM	Heard on the Street Monday Recap: Homebuilder Industry Strikes Back (The Wall Street Journal)
12:01AM	Novo Nordisk Launches Suit to Knock Out Hims & Hers Weight Loss Knockoffs (The Daily Upside)
12:01AM	Morgan Stanley Begins Coverage Of Bitcoin Miners As Wider Infrastructure Plays (The Daily Upside)
Feb-09-26 05:45PM	Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts (Zacks) -16.03%
05:23PM	Hims & Hers stock plunges after weight loss pill pulled amid FDA scrutiny (CBS News Videos)
05:20PM	Loading…
05:20PM	Stocks to Watch Monday Recap: Novo Nordisk, Hims & Hers, Apollo (The Wall Street Journal)
04:42PM	Stock Market Today: Dow Up As Oracle Soars; Cathie Wood Buys Buffett Stock Amid 145% Run (Live Coverage) (Investor's Business Daily)
04:34PM	Stocks Settle Higher on Strength in Tech (Barchart)
04:19PM	These Stocks Are Todays Movers: Kyndryl, Hims & Hers, Novo Nordisk, Oracle, Nvidia, AppLovin, and More (Barrons.com)
03:44PM	Novo Nordisk, Hims & Hers Health Shares React to Lawsuit (Schaeffer's Research)
03:42PM	Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo (The Wall Street Journal)
02:27PM	Analyst Report: Hims & Hers Health, Inc. (Morningstar Research)
02:23PM	Nasdaq powers ahead as Dow adds to gains in afternoon trading (Proactive)
02:19PM	Novo Nordisk Escalates Fight Against Hims & Hers (The Wall Street Journal)
02:13PM	Stock Market Today: Dow Firm As Oracle Soars On This; Hims & Hers Shares Crater On Novo Move (Live Coverage) (Investor's Business Daily)
01:44PM	FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast (Benzinga)
01:03PM	Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War (Benzinga)
12:28PM	Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans (Benzinga)
11:59AM	HIMs 22% Collapse Looks Like A Buy The Dip Moment (24/7 Wall St.)
11:55AM	Why Hims & Hers Health (HIMS) Stock Is Nosediving (StockStory)
11:33AM	Loading…
11:33AM	Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn (Investopedia)
11:25AM	Novo sues Hims & Hers despite Wegovy pill offering U-turn (Pharmaceutical Technology)
11:22AM	Dow Jones retreat from highs as Amazon and Apple fall (Proactive)
11:06AM	Stock Market Today: Dow Gains As Nvidia Jumps; Apple Lags, Energy Stock Tests Entry (Live Coverage) (Investor's Business Daily)
11:01AM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
10:49AM	Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds (Yahoo Finance)
10:24AM	HIMS Stock Tumbles as FDA Scrutiny Boosts Novo Nordisk Shares (GuruFocus.com)
10:24AM	Hims & Hers Plummets On FDA Crackdown, Novo Nordisk Lawsuit (Investor's Business Daily)
10:18AM	Stock Market Today: Dow Skids Even As Nvidia Jumps; Monday Plunges, Biopharma Funds Lag (Live Coverage) (Investor's Business Daily)
10:06AM	Novo Nordisk sues Hims & Hers over knockoff weight loss drugs (Quartz)
09:55AM	Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead? (Zacks)
09:46AM	Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs (Benzinga)
09:44AM	Stock Market Today: Dow Falls As Jobs Report Looms; AI Player Monday Plunges On Earnings (Live Coverage) (Investor's Business Daily)
09:37AM	Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill (The Wall Street Journal)
09:28AM	Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges (Yahoo Finance Video)
09:25AM	Novo Nordisk Sues Hims & Hers, Seeking Ban on Copycat Drugs and Damages (The Wall Street Journal)
09:04AM	Hims & Hers scraps low-cost weight-loss pill following backlash (Proactive)
09:00AM	Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock (Zacks)
08:12AM	Hims & Hers Stock Plunges. Its Weight Loss Drug Strategy Backfired. (Barrons.com)
08:07AM	Novo Nordisk Files Lawsuit Against Hims & Hers, Seeking Ban on Copycat Drugs and Damages (The Wall Street Journal)
07:39AM	Novo Nordisk Surges as Hims & Hers Withdraws Weight-Loss Pill (GuruFocus.com)
07:36AM	Hims & Hers slumps on Wegovy backtrack and more early-moving stocks (MarketWatch)
07:28AM	Wegovy maker sues Hims & Hers after company launches $49 weight-loss pill (USA TODAY)
07:18AM	Hims & Hers Pulls Compounded Weight-Loss Pill After FDA Warning (GuruFocus.com)
07:04AM	3 Things That Can Ease Stock Market Nerves as Crucial Jobs Report Looms (Barrons.com)
06:53AM	Novo Nordisk Shares Jump After Hims & Hers Scraps Plan for Copycat Weight-Loss Pill (The Wall Street Journal)
06:42AM	Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why (Investor's Business Daily)
06:02AM	These Stocks Are Today's Movers: Hims & Hers, Micron, Kroger, STMicroelectronics, Nvidia, Amazon, and More (Barrons.com)
05:11AM	Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow. (Barrons.com)
05:07AM	Novo Nordisk Stock Jumps After Hims & Hers Scraps Copycat Weight-Loss Pill (The Wall Street Journal)
03:53AM	Novo Nordisk shares jumps as Hims pulls $49 compounded weight-loss pill (Investing.com)
03:30AM	Hims & Hers Super Bowl Ad For Cancer Test Raises Questions Over Reliability (Benzinga)
03:30AM	Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor (MarketWatch)
02:45AM	Novo Nordisk shares rise as Hims abandons $49 weight-loss pill (Reuters)
Feb-08-26 08:39AM	Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
07:57AM	Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning (Benzinga)
Feb-07-26 05:35PM	Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill (Associated Press Finance)
05:27PM	Hims & Hers Health Stops Offering Wegovy Pill Knockoff Over FDA Crackdown (Investor's Business Daily)
05:22PM	Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown (Investor's Business Daily)
04:22PM	Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny (Barrons.com)
03:32PM	Hims & Hers abandons copycat weight-loss drug in face of FDA probe (Financial Times)
11:16AM	Hims cancels plans to sell compounded GLP-1 pill after FDA backlash (BioPharma Dive)
09:31AM	Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action (Benzinga)
09:03AM	FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown (24/7 Wall St.)
06:07AM	Weight-loss drugs to compete on biggest stage with Super Bowl ads (Reuters)
05:30AM	The Weight-Loss Price Wars Are Breaking Big Pharma's Business Model (The Wall Street Journal)
Feb-06-26 08:22PM	Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. (Barrons.com) -16.03%
06:29PM	Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department (The Wall Street Journal)
05:45PM	FDA scrutiny rattles Hims & Hers stock (Investing.com)
05:45PM	Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut (MarketBeat)
05:41PM	Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. (Barrons.com)
04:13PM	Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers (Barrons.com)
03:29PM	Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill (MarketWatch)
01:51PM	What's Going On With Novo Nordisk Stock On Friday? (Benzinga)
01:12PM	FDA warns against illegal copycat drugs, Molina stock sinks (Yahoo Finance Video)
12:38PM	These Stocks Are Todays Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More (Barrons.com)
11:52AM	Hims & Hers Stock Drops. It May Be Losing Its Weight-Loss Battle With Novo. (Barrons.com)
10:41AM	Novo Nordisk Shares Slide 21% After Forecast Cut, Copycat Wegovy Pill Launch (GuruFocus.com)
10:37AM	Hims & Hers falls ~8% premarket after FDA warning on copycat drugs (GuruFocus.com)
10:28AM	Hims & Hers Strengthens Platform-Led Digital Healthcare Model (Zacks)
09:27AM	NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill (Zacks)
08:22AM	Hims & Hers stock falls after FDA warns against illegal copycat drugs (Investing.com)
07:52AM	Novos Stratospheric Rise Has Turned Into a $460 Billion Wipeout (Bloomberg)
07:36AM	Novo Nordisk Rebounds After FDA Signals Crackdown on Copycat Drugs (GuruFocus.com)
07:22AM	FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint (Pharmaceutical Technology)
07:17AM	Citi flags lingering risks to Novo despite strong weight-loss portfolio (Proactive)
07:04AM	Novo Stock Jumps, Hims & Hers Tanks. This Could Shift the Weight-Loss Copycat Battle. (Barrons.com)
07:02AM	Novo Nordisk Shares Rebound as FDA Moves Against Illegal Drug Copies (GuruFocus.com)
06:47AM	Amazon Defies AI Fears With Huge Spending. Why It's a Big Risk for Markets. (Barrons.com)
04:51AM	Novo shares rebound as FDA vows crackdown on weight-loss drug copies (Investing.com)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Okupe Oluyemi	Chief Financial Officer	Feb 03 '26	Option Exercise	5.01	5,262	26,363	96,879	Feb 04 04:13 PM
Okupe Oluyemi	Chief Financial Officer	Feb 03 '26	Sale	26.44	5,262	139,108	91,617	Feb 04 04:13 PM
Okupe Oluyemi	Chief Financial Officer	Jan 20 '26	Option Exercise	6.27	9,067	56,836	100,684	Jan 21 04:23 PM
Okupe Oluyemi	Chief Financial Officer	Jan 20 '26	Sale	30.34	9,067	275,114	91,617	Jan 21 04:23 PM
Oluyemi Okupe	Officer	Jan 20 '26	Proposed Sale	30.47	27,204	828,906		Jan 20 04:34 PM
Okupe Oluyemi	Chief Financial Officer	Jan 05 '26	Option Exercise	9.16	5,986	54,818	100,687	Jan 07 04:16 PM
Okupe Oluyemi	Chief Financial Officer	Jan 05 '26	Sale	33.79	9,070	306,453	91,617	Jan 07 04:16 PM
Okupe Oluyemi	Chief Financial Officer	Dec 22 '25	Sale	35.72	23,090	824,710	94,333	Dec 23 04:15 PM
Oluyemi Okupe	Officer	Dec 22 '25	Proposed Sale	35.05	32,160	1,127,208		Dec 22 05:00 PM
Chi Michael	Chief Operating Officer	Dec 17 '25	Sale	36.71	13,750	504,762	305,161	Dec 18 04:15 PM
Autor Deborah M.	Chief Policy Officer	Dec 17 '25	Sale	36.71	7,054	258,952	6,175	Dec 18 04:15 PM
Carroll Patrick Harrison	Chief Medical Officer	Dec 17 '25	Sale	36.71	10,021	367,871	169,940	Dec 18 04:15 PM
Becklund Irene	PAO	Dec 17 '25	Sale	36.71	8,411	308,768	2,126	Dec 18 04:15 PM
Carroll Patrick Harrison	Officer	Dec 17 '25	Proposed Sale	36.71	10,021	367,871		Dec 17 10:26 AM
Chi Michael	Officer	Dec 17 '25	Proposed Sale	36.71	13,750	504,762		Dec 17 10:14 AM
Becklund Irene	Officer	Dec 17 '25	Proposed Sale	36.71	8,411	308,768		Dec 17 09:50 AM
Autor Deborah M.	Officer	Dec 17 '25	Proposed Sale	36.71	7,054	258,952		Dec 17 09:42 AM
Perez Garcia Andrea G	Director	Dec 09 '25	Sale	39.17	2,500	97,925	80,166	Dec 10 04:35 PM
Perez Garcia Andrea G	Director	Dec 09 '25	Proposed Sale	39.17	2,500	97,925		Dec 09 10:07 AM
Boughton Soleil	Chief Legal Officer	Nov 24 '25	Sale	35.22	2,631	92,664	153,225	Nov 25 04:13 PM
Boughton Soleil	Officer	Nov 24 '25	Proposed Sale	35.11	2,631	92,374		Nov 24 10:03 AM
Okupe Oluyemi	Chief Financial Officer	Nov 17 '25	Option Exercise	7.15	23,187	165,817	93,419	Nov 19 04:31 PM
Okupe Oluyemi	Chief Financial Officer	Nov 17 '25	Sale	36.81	23,187	853,490	70,232	Nov 19 04:31 PM
Boughton Soleil	Chief Legal Officer	Nov 10 '25	Sale	42.53	2,637	112,152	155,856	Nov 12 08:02 PM
Boughton Soleil	Officer	Nov 10 '25	Proposed Sale	42.53	2,637	112,152		Nov 10 10:16 AM
Boughton Soleil	Chief Legal Officer	Oct 27 '25	Sale	50.10	2,637	132,114	158,493	Oct 28 04:23 PM
Boughton Soleil	Officer	Oct 27 '25	Proposed Sale	50.10	2,637	132,114		Oct 27 09:42 AM
Okupe Oluyemi	Chief Financial Officer	Oct 17 '25	Option Exercise	7.15	11,592	82,898	81,824	Oct 20 04:42 PM
Okupe Oluyemi	Chief Financial Officer	Oct 17 '25	Sale	57.13	11,592	662,222	70,232	Oct 20 04:42 PM
Dudum Andrew	Officer	Oct 16 '25	Proposed Sale	62.79	175,661	11,029,998		Oct 16 03:10 PM
Chi Michael	Chief Commercial Officer	Oct 10 '25	Option Exercise	6.82	900	6,138	292,339	Oct 14 04:17 PM
Chi Michael	Chief Commercial Officer	Oct 10 '25	Sale	58.25	900	52,425	291,439	Oct 14 04:17 PM
Boughton Soleil	Chief Legal Officer	Oct 13 '25	Sale	54.38	2,637	143,400	161,130	Oct 14 04:17 PM
Boughton Soleil	Officer	Oct 13 '25	Proposed Sale	54.38	2,637	143,400		Oct 14 06:47 AM
Chi Michael	Officer	Oct 10 '25	Proposed Sale	58.25	900	52,425		Oct 10 11:26 AM
Okupe Oluyemi	Chief Financial Officer	Oct 03 '25	Option Exercise	7.15	11,595	82,919	81,827	Oct 07 04:47 PM
Okupe Oluyemi	Chief Financial Officer	Oct 03 '25	Sale	57.72	11,595	669,232	70,232	Oct 07 04:47 PM
Chi Michael	Chief Commercial Officer	Oct 01 '25	Option Exercise	11.53	250	2,882	291,689	Oct 02 04:10 PM
Chi Michael	Chief Commercial Officer	Oct 01 '25	Sale	56.00	250	14,000	291,439	Oct 02 04:10 PM
Chi Michael	Officer	Oct 01 '25	Proposed Sale	56.00	250	14,000		Oct 01 11:34 AM
Okupe Oluyemi	Chief Financial Officer	Sep 29 '25	Option Exercise	5.01	49,832	249,658	155,232	Sep 30 04:33 PM
Okupe Oluyemi	Chief Financial Officer	Sep 29 '25	Sale	60.20	85,000	5,116,924	70,232	Sep 30 04:33 PM
Boughton Soleil	Chief Legal Officer	Sep 29 '25	Sale	58.79	2,637	155,029	163,767	Sep 30 04:33 PM
Boughton Soleil	Officer	Sep 29 '25	Proposed Sale	58.79	2,637	155,029		Sep 29 09:51 AM
Chi Michael	Chief Commercial Officer	Sep 24 '25	Option Exercise	5.01	2,100	10,521	293,539	Sep 25 06:06 PM
Chi Michael	Chief Commercial Officer	Sep 24 '25	Sale	56.52	2,100	118,692	291,439	Sep 25 06:06 PM
Okupe Oluyemi	Chief Financial Officer	Sep 22 '25	Sale	57.74	23,584	1,361,766	105,400	Sep 24 04:22 PM
Chi Michael	Officer	Sep 24 '25	Proposed Sale	56.52	2,100	118,692		Sep 24 11:02 AM
Oluyemi Okupe	Officer	Sep 22 '25	Proposed Sale	57.70	154,958	8,941,077		Sep 22 05:39 PM
Boughton Soleil	Chief Legal Officer	Sep 17 '25	Sale	50.50	2,637	133,168	166,404	Sep 19 04:28 PM
Carroll Patrick Harrison	Chief Medical Officer	Sep 17 '25	Sale	50.50	10,021	506,060	169,940	Sep 19 04:28 PM
Becklund Irene	PAO	Sep 17 '25	Sale	50.50	8,410	424,705	1,418	Sep 19 04:28 PM
Chi Michael	Chief Commercial Officer	Sep 17 '25	Sale	50.50	13,749	694,324	297,139	Sep 19 04:27 PM
Dudum Andrew	Chief Executive Officer	Sep 17 '25	Sale	50.57	65,110	3,292,906	95,315	Sep 19 04:27 PM
Chi Michael	Chief Commercial Officer	Sep 15 '25	Option Exercise	6.19	4,150	25,680	282,804	Sep 17 07:24 PM
Chi Michael	Chief Commercial Officer	Sep 15 '25	Sale	56.00	4,150	232,400	278,654	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Option Exercise	2.43	125,335	304,564	268,759	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Sale	53.48	128,127	6,852,300	160,425	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Sale	53.27	47,534	2,532,325	95,058	Sep 17 07:24 PM
Okupe Oluyemi	Chief Financial Officer	Sep 15 '25	Option Exercise	5.01	110,000	551,100	273,984	Sep 17 07:24 PM
Okupe Oluyemi	Chief Financial Officer	Sep 15 '25	Sale	55.35	145,000	8,026,076	128,984	Sep 17 07:24 PM
Dudum Andrew	Officer	Sep 17 '25	Proposed Sale	50.57	65,110	3,292,904		Sep 17 12:44 PM
Boughton Soleil	Officer	Sep 17 '25	Proposed Sale	50.50	2,637	133,168		Sep 17 11:15 AM
Carroll Patrick Harrison	Officer	Sep 17 '25	Proposed Sale	50.50	10,021	506,060		Sep 17 10:20 AM
Chi Michael	Officer	Sep 17 '25	Proposed Sale	50.50	13,749	694,324		Sep 17 10:07 AM
Becklund Irene	Officer	Sep 17 '25	Proposed Sale	50.50	8,410	424,705		Sep 17 09:50 AM
Dudum Andrew	Officer	Sep 16 '25	Proposed Sale	53.42	175,661	9,384,626		Sep 16 11:29 AM
Oluyemi Okupe	Officer	Sep 15 '25	Proposed Sale	53.96	145,000	7,824,200		Sep 15 06:35 PM
Chi Michael	Officer	Sep 15 '25	Proposed Sale	56.00	4,150	232,400		Sep 15 11:49 AM
Okupe Oluyemi	Chief Financial Officer	Aug 26 '25	Option Exercise	5.01	11,581	58,021	128,387	Aug 28 04:34 PM
Okupe Oluyemi	Chief Financial Officer	Aug 26 '25	Sale	43.69	11,581	505,968	116,806	Aug 28 04:34 PM
Boughton Soleil	Chief Legal Officer	Aug 25 '25	Sale	44.53	2,571	114,487	150,450	Aug 26 04:35 PM
Boughton Soleil	Officer	Aug 25 '25	Proposed Sale	44.53	2,571	114,487		Aug 25 09:46 AM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Option Exercise	2.43	125,335	304,564	197,855	Aug 20 04:14 PM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Sale	45.06	128,127	5,773,242	89,521	Aug 20 04:14 PM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Sale	45.05	47,534	2,141,492	142,592	Aug 20 04:14 PM
Dudum Andrew	Officer	Aug 18 '25	Proposed Sale	45.05	47,534	2,141,494		Aug 18 12:33 PM
Dudum Andrew	Officer	Aug 18 '25	Proposed Sale	45.22	128,127	5,793,903		Aug 18 10:22 AM
Okupe Oluyemi	Chief Financial Officer	Aug 13 '25	Option Exercise	5.01	11,581	58,021	65,665	Aug 15 04:18 PM
Okupe Oluyemi	Chief Financial Officer	Aug 13 '25	Sale	48.05	11,581	556,420	116,806	Aug 15 04:18 PM
Melissa Baird	Officer	Aug 12 '25	Proposed Sale	47.96	33,333	1,598,651		Aug 12 05:22 PM
Boughton Soleil	Chief Legal Officer	Aug 11 '25	Sale	51.64	2,572	132,818	153,021	Aug 12 04:33 PM
Dudum Andrew	Chief Executive Officer	Aug 07 '25	Sale	50.58	660,000	33,384,120	2,214,769	Aug 11 05:07 PM
Boughton Soleil	Officer	Aug 11 '25	Proposed Sale	51.64	2,572	132,818		Aug 11 10:18 AM
Carroll Patrick Harrison	Chief Medical Officer	Aug 06 '25	Sale	53.58	60,000	3,214,878	169,940	Aug 08 04:19 PM
Carroll Patrick Harrison	Officer	Aug 06 '25	Proposed Sale	53.58	60,000	3,214,881		Aug 06 01:27 PM
Chi Michael	Chief Commercial Officer	Jul 31 '25	Option Exercise	7.09	26,350	186,830	305,004	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Aug 01 '25	Option Exercise	11.53	250	2,882	278,904	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Jul 31 '25	Sale	67.00	26,350	1,765,450	278,654	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Aug 01 '25	Sale	64.44	250	16,110	278,654	Aug 04 04:21 PM
Chi Michael	Officer	Aug 01 '25	Proposed Sale	64.44	250	16,110		Aug 01 11:12 AM
Chi Michael	Officer	Jul 31 '25	Proposed Sale	67.00	26,350	1,765,450		Jul 31 11:02 AM
Boughton Soleil	Chief Legal Officer	Jul 28 '25	Sale	58.70	2,572	150,976	155,593	Jul 29 04:25 PM
Boughton Soleil	Officer	Jul 28 '25	Proposed Sale	58.70	2,572	150,976		Jul 28 12:59 PM
Chi Michael	Chief Commercial Officer	Jul 23 '25	Option Exercise	5.25	13,750	72,146	292,404	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 24 '25	Option Exercise	5.01	2,100	10,521	280,754	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 23 '25	Sale	56.00	13,750	770,000	278,654	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 24 '25	Sale	57.52	2,100	120,792	278,654	Jul 25 05:20 PM
Chi Michael	Officer	Jul 24 '25	Proposed Sale	57.52	2,100	120,792		Jul 24 10:44 AM
Dudum Andrew	Chief Executive Officer	Jul 21 '25	Option Exercise	2.43	125,335	304,564	142,313	Jul 23 04:12 PM

AMRX Amneal Pharmaceuticals Inc daily Stock Chart

Peers: JNJ PFE NVS TAK TEVA PRGO FMS RDY SNN

| Held by: IJR VTI IWM VB VBR VXF SPSM IWO DFAS PJP

Index	RUT	P/E	1035.21	EPS (ttm)	0.01	Insider Own	50.13%	Shs Outstand	314.31M	Perf Week	1.87%
Market Cap	4.62B	Forward P/E	15.65	EPS next Y	0.94	Insider Trans	-0.81%	Shs Float	156.78M	Perf Month	13.25%
Enterprise Value	7.14B	PEG	0.62	EPS next Q	0.18	Inst Own	45.58%	Short Float	8.09%	Perf Quarter	28.05%
Income	5.90M	P/S	1.57	EPS this Y	37.93%	Inst Trans	4.35%	Short Ratio	5.19	Perf Half Y	62.97%
Sales	2.93B	P/B	-	EPS next Y	17.43%	ROA	0.17%	Short Interest	12.69M	Perf YTD	16.67%
Book/sh	-0.35	P/C	19.58	EPS next 5Y	25.10%	ROE	-	52W High	15.00 -2.00%	Perf Year	84.67%
Cash/sh	0.75	P/FCF	18.52	EPS past 3/5Y	- 32.70%	ROIC	0.23%	52W Low	6.68 119.90%	Perf 3Y	541.92%
Dividend Est.	-	EV/EBITDA	11.80	Sales past 3/5Y	10.10% 11.43%	Gross Margin	36.76%	Volatility	3.00% 3.29%	Perf 5Y	149.15%
Dividend TTM	-	EV/Sales	2.43	EPS Y/Y TTM	102.62%	Oper. Margin	12.41%	ATR (14)	0.44	Perf 10Y	-52.16%
Dividend Ex-Date	-	Quick Ratio	1.42	Sales Y/Y TTM	9.50%	Profit Margin	0.20%	RSI (14)	68.18	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	2.13	EPS Q/Q	1560.00%	SMA20	5.32%	Beta	1.34	Target Price	15.20
Payout	-	Debt/Eq	-	Sales Q/Q	11.68%	SMA50	12.04%	Rel Volume	0.61	Prev Close	14.76
Employees	8300	LT Debt/Eq	-	Earnings	Feb 27 BMO	SMA200	45.23%	Avg Volume	2.44M	Price	14.70
IPO	Dec 19, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.92% 1.38%	Trades		Volume	1,480,911	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$15
Jun-06-25	Initiated	Goldman	Buy	$12
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight	$9 → $12
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral	$9
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$5
Mar-08-21	Upgrade	Goldman	Sell → Buy	$4 → $6.50
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy	$5.50
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight	$4.50 → $6
Jul-27-20	Initiated	Goldman	Sell	$4
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$11 → $5
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11 → $6
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight	$9
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy	$13
Mar-20-19	Initiated	SunTrust	Buy	$16
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$16 → $12

Show Previous Ratings

Feb-09-26 09:40AM	Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
Feb-05-26 09:40AM	Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now? (Zacks)
Feb-04-26 11:32PM	3 Small-Cap Stocks That Fall Short (StockStory)
Feb-03-26 11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
04:05PM	Loading…
Jan-28-26 04:05PM	Amneal Pharmaceuticals Added to S&P SmallCap 600 Index (GlobeNewswire)
12:10PM	Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
Jan-27-26 06:02PM	TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 (PR Newswire)
12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
08:00AM	Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 (GlobeNewswire)
Jan-25-26 11:02PM	2 Reasons to Sell AMRX and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-26 09:40AM	Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? (Zacks)
Jan-13-26 09:04PM	Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 (MarketBeat)
02:57PM	Loading…
Jan-10-26 02:57PM	Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 (Insider Monkey)
Jan-07-26 02:55PM	Can This Healthcare Stock Keep Going After a Nearly 70% Surge? (Barchart)
Jan-06-26 11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
Dec-22-25 04:01PM	Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (GlobeNewswire)
04:00PM	mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (PR Newswire)
Dec-09-25 04:01PM	Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals (GlobeNewswire)
Dec-05-25 08:00AM	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease (GlobeNewswire)
Dec-02-25 08:00AM	Amneal to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol (GlobeNewswire)
Dec-01-25 04:01PM	Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% (GlobeNewswire)
Nov-28-25 10:56AM	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 10:33PM	Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
05:10AM	Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat (Insider Monkey)
04:01PM	Loading…
Nov-13-25 04:01PM	Amneal Receives U.S. FDA Approval for Iohexol Injection (GlobeNewswire)
Nov-11-25 11:35PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Nov-04-25 09:33AM	Implied Volatility Surging for Amneal Pharmaceuticals Stock Options (Zacks)
Oct-31-25 01:00PM	Why Amneal (AMRX) Stock Is Up Today (StockStory) +8.20%
Oct-30-25 04:30PM	Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:30AM	Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:47AM	Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars (StockStory)
06:14AM	Amneal: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 04:05PM	Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (GlobeNewswire)
09:39AM	What To Expect From Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 11:17PM	Amneal Earnings: What To Look For From AMRX (StockStory)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches (GlobeNewswire)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-21-25 10:42PM	Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory (Insider Monkey)
Oct-07-25 09:40AM	Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? (Zacks)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
Oct-03-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Oct-01-25 01:44PM	Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR Biosimilar, Targets Multi-Billion-Dollar Market (Insider Monkey)
Sep-30-25 04:05PM	Amneal to Report Third Quarter 2025 Results on October 30, 2025 (GlobeNewswire)
Sep-26-25 08:00AM	Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) (GlobeNewswire)
Sep-23-25 08:00AM	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% (GlobeNewswire)
Sep-15-25 05:29AM	Amneal secures FDA approval for sodium oxybate solution (Pharmaceutical Technology)
Sep-11-25 02:16PM	Why Amneal (AMRX) Stock Is Up Today (StockStory)
08:00AM	Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution (GlobeNewswire)
Sep-04-25 04:01PM	Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet (Zacks)
Aug-25-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
Aug-14-25 09:55AM	Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? (Zacks)
Aug-13-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
08:50AM	Here's Why Momentum in Amneal (AMRX) Should Keep going (Zacks)
12:09AM	AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance (StockStory)
Aug-12-25 11:52PM	5 Revealing Analyst Questions From Amneal's Q2 Earnings Call (StockStory)
Aug-05-25 09:30AM	Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30AM	Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico (GlobeNewswire)
07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
06:16AM	Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets (StockStory)
06:14AM	Amneal: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 02:07PM	Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
09:35AM	Amneal Pharmaceuticals Inc (AMRX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-03-25 11:08PM	Amneal Earnings: What To Look For From AMRX (StockStory)
Jul-31-25 02:44PM	Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT (Insider Monkey)
Jul-29-25 12:45PM	Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
10:00AM	Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Jul-28-25 11:31PM	Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
09:40AM	Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? (Zacks)
12:04AM	2 Reasons to Avoid AMRX and 1 Stock to Buy Instead (StockStory)
Jul-21-25 07:39AM	Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 (GlobeNewswire)
07:38AM	Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-18-25 07:00AM	Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada (GlobeNewswire)
Jul-11-25 11:27AM	Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension (Insider Monkey)
Jul-09-25 08:00AM	Amneal to Report Second Quarter 2025 Results on August 5, 2025 (GlobeNewswire)
Jul-02-25 10:09PM	Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares (Insider Monkey)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-26-25 05:46PM	5 Revealing Analyst Questions From Amneal's Q1 Earnings Call (StockStory)
Jun-25-25 08:00AM	Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences (GlobeNewswire)
Jun-17-25 10:00AM	Generic Drugmakers Resist Trumps Calls for More U.S. Manufacturing (The Wall Street Journal)
Jun-13-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Jun-12-25 08:00AM	Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension (GlobeNewswire)

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nark Ted C	Director	Nov 17 '25	Sale	11.72	50,000	586,000	291,029	Nov 19 04:21 PM
Nark Ted C	Director	Nov 17 '25	Proposed Sale	11.82	50,000	591,250		Nov 17 03:06 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Option Exercise	2.75	131,856	362,604	278,259	Nov 14 05:13 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Sale	11.92	131,856	1,571,724	146,403	Nov 14 05:13 PM
NIKITA SHAH	OFFICER	Nov 12 '25	Proposed Sale	11.92	131,856	1,571,723		Nov 12 05:12 PM
Kiely John	Director	Aug 27 '25	Sale	9.23	32,000	295,360	225,433	Aug 28 04:25 PM
Kiely John	Director	Aug 27 '25	Proposed Sale	9.18	32,000	293,810		Aug 27 03:04 PM
Shah Nikita	Executive Vice President	Aug 22 '25	Sale	9.66	114,492	1,105,993	152,743	Aug 25 04:27 PM
Shah Nikita	Executive Vice President	Aug 25 '25	Sale	9.50	6,340	60,230	146,403	Aug 25 04:27 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Option Exercise	2.75	175,000	481,250	431,670	Aug 22 04:38 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Sale	9.38	279,244	2,619,309	152,426	Aug 22 04:38 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.70	36,796	356,921		Aug 22 04:03 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.74	84,036	818,931		Aug 22 12:18 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.36	175,000	1,637,900		Aug 20 04:16 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.30	104,244	969,469		Aug 20 10:26 AM
Shah Nikita	Executive Vice President	Aug 14 '25	Sale	9.29	71,694	666,037	267,235	Aug 15 04:31 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 15 '25	Sale	9.43	219,159	2,066,669	122,152	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 13 '25	Sale	9.22	161,365	1,487,785	460,517	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 14 '25	Sale	9.30	119,206	1,108,616	341,311	Aug 15 04:30 PM
Konidaris Tasos	Officer	Aug 15 '25	Proposed Sale	9.39	219,159	2,057,903		Aug 15 11:14 AM
Shah Nikita	Officer	Aug 14 '25	Proposed Sale	9.25	71,694	663,065		Aug 14 04:10 PM
Shah Nikita	Executive Vice President	Aug 12 '25	Sale	9.04	50,000	452,000	338,929	Aug 13 04:40 PM
Daly Jason B.	EVP, Chief Legal Officer	Aug 12 '25	Sale	9.05	22,000	199,100	10,606	Aug 13 04:39 PM
BOYER ANDREW S	Executive Vice President	Aug 12 '25	Sale	9.05	33,436	302,596	256,670	Aug 13 04:38 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.27	169,206	1,568,539		Aug 13 03:08 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.02	111,635	1,006,947		Aug 13 10:41 AM
BOYER ANDREW S	Officer	Aug 12 '25	Proposed Sale	9.09	33,436	304,100		Aug 12 04:06 PM
Daly Jason B.	Officer	Aug 12 '25	Proposed Sale	9.00	22,000	198,000		Aug 12 04:04 PM
Shah Nikita	Officer	Aug 12 '25	Proposed Sale	9.06	50,000	453,000		Aug 12 03:09 PM
Patel Gautam	Director	Jun 16 '25	Sale	8.02	94,906	761,146	1,609,144	Jun 18 04:11 PM
Patel Gautam	Director	Jun 10 '25	Sale	8.02	56,426	452,537	1,704,050	Jun 12 04:19 PM
Shah Nikita	Executive Vice President	May 16 '25	Sale	7.58	49,140	372,481	388,929	May 19 04:16 PM
Shah Nikita	Officer	May 16 '25	Proposed Sale	7.50	49,140	368,550		May 16 04:02 PM
Kiely John	Director	May 12 '25	Sale	7.59	50,000	379,500	257,433	May 13 04:42 PM
Kiely John	Director	May 12 '25	Proposed Sale	7.57	50,000	378,500		May 12 04:07 PM
Patel Gautam	Director	May 05 '25	Sale	8.00	4,900	39,200	1,720,218	May 06 04:29 PM
Patel Gautam	Director	May 02 '25	Sale	8.00	3,768	30,144	1,725,118	May 06 04:29 PM
Gautam Patel	Director	May 02 '25	Proposed Sale	7.74	160,000	1,238,400		May 02 04:38 PM
Patel Gautam	Director	Apr 01 '25	Sale	8.30	80,000	664,000	1,728,886	Apr 02 04:12 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Sale	8.35	5,000,000	41,750,000	48,578,209	Mar 17 04:51 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Proposed Sale	8.75	5,000,000	43,750,000		Mar 14 07:32 PM
BOYER ANDREW S	Executive Vice President	Mar 05 '25	Sale	8.89	125,000	1,111,250	290,106	Mar 07 04:18 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 06 '25	Sale	8.73	46,936	409,751	32,606	Mar 07 04:17 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 05 '25	Sale	8.88	43,064	382,408	79,542	Mar 07 04:17 PM
Konidaris Tasos	Executive Vice President & CFO	Mar 05 '25	Sale	8.91	100,000	891,000	621,882	Mar 07 04:17 PM
Alva Emily Peterson	Director	Mar 05 '25	Sale	8.90	80,000	712,000	170,771	Mar 07 04:16 PM
Patel Gautam	Director	Mar 03 '25	Sale	8.90	80,000	712,000	1,808,886	Mar 05 07:12 PM
Alva Emily Peterson	Director	Mar 05 '25	Proposed Sale	8.87	85,000	753,950		Mar 05 05:02 PM
BOYER ANDREW S	Officer	Mar 05 '25	Proposed Sale	8.87	125,000	1,108,750		Mar 05 05:00 PM
Daly Jason B.	Officer	Mar 05 '25	Proposed Sale	8.80	90,000	792,000		Mar 05 04:57 PM
Konidaris Tasos	Officer	Mar 05 '25	Proposed Sale	8.84	100,000	884,000		Mar 05 10:00 AM

HIMS

Hims & Hers Health Inc

AMRX

Amneal Pharmaceuticals Inc

Upgrade your FINVIZ experience